Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma

Jiang,Haiyan; Xi,Qinghua; Wang,Feiran; Sun,Zhichao; Huang,Zhongwei; Qi,Lei

doi:10.3892/mmr.2015.3580

Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma

Authors:
- Haiyan Jiang
- Qinghua Xi
- Feiran Wang
- Zhichao Sun
- Zhongwei Huang
- Lei Qi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Medical College, Nantong University, Nantong, Jiangsu 226019, P.R. China, Department of Emergency Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: April 1, 2015 https://doi.org/10.3892/mmr.2015.3580
Pages: 2114-2120

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuropilin 1 (NRP1) is a transmembrane glycoprotein, which interacts with vascular endothelial growth factor to prevent tumor cell apoptosis and to regulate angiogenesis. However, the precise role of NRP1 in epithelial ovarian carcinoma (EOC) remains to be elucidated. The present study aimed to determine the association between NRP1 and EOC. The expression of NRP1 in ovarian cancer and normal ovarian epithelial tissues was investigated by immunofluorescence, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting. The association between the expression of NRP1 with the development of ovarian cancer, clinicopathological characteristics and survival were also analyzed. The results from immunofluorescence, RT‑qPCR and western blot analysis demonstrated that NRP1 exhibited significant upregulation in EOC compared with normal ovarian epithelial specimens (P<0.05). The positive expression of NRP1 was higher in cancer tissues at an advanced International Federation of Gynecology and Obstetrics stage, and in cancer tissues with lymph node metastasis and distant metastasis compared with that in cancer tissues without lymph node or distant metastasis (P<0.05). Higher NRP1 expression strongly predicted a shorter survival time (P<0.001). The present findings suggested that increased NRP1 expression may be associated with the development of EOC. Therefore, NRP1 could be used as a valuable prognostic marker as well as a potential molecular therapy target for ovarian cancer patients.

View Figures

View References

1	Paes MF, Daltoé RD, Madeira KP, et al: A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the state of Espírito Santo, Brazil. J Ovarian Res. 4:142011. View Article : Google Scholar
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Hudson LG, Zeineldin R and Stack MS: Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis. 25:643–655. 2008. View Article : Google Scholar : PubMed/NCBI
4	Domenighetti G, Moccia A and Gayer R: Observational case-control study of non-invasive ventilation in patients with ARDS. Monaldi Arch Chest Dis. 69:5–10. 2008.PubMed/NCBI
5	Teoh D and Secord AA: Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer. 22:348–359. 2012. View Article : Google Scholar : PubMed/NCBI
6	Usha L, Sill MW, Darcy KM, et al: A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 121:455–461. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wu H, Yao L, Mei J and Li F: Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Pathol. 8:207–216. 2015.PubMed/NCBI
8	Kannan K, Coarfa C, Chao PW, et al: Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma. Proc Natl Acad Sci USA. 112:E1272–E1277. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gurler H, Yu Y, Choi J, Kajdacsy-Balla AA and Barbolina MV: Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma. Int J Mol Sci. 16:3419–3433. 2015. View Article : Google Scholar : PubMed/NCBI
10	Morris LG, Veeriah S and Chan TA: Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene. 29:3453–3464. 2010. View Article : Google Scholar : PubMed/NCBI
11	Gan GN, Weickhardt AJ, Scheier B, et al: Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 88:892–898. 2014. View Article : Google Scholar : PubMed/NCBI
12	Catalano A, Caprari P, Rodilossi S, et al: Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J. 18:358–360. 2004.
13	Cao L, Liu X, Lin EJ, et al: Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell. 142:52–64. 2010. View Article : Google Scholar : PubMed/NCBI
14	Casazza A, Fu X, Johansson I, et al: Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol. 31:741–749. 2011. View Article : Google Scholar : PubMed/NCBI
15	Maione F, Molla F, Meda C, et al: Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest. 119:3356–3372. 2009.PubMed/NCBI
16	Sakurai A, Gavard J, Annas-Linhares Y, et al: Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras. Mol Cell Biol. 30:3086–3098. 2010. View Article : Google Scholar : PubMed/NCBI
17	Varshavsky A, Kessler O, Abramovitch S, et al: Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. Cancer Res. 68:6922–6931. 2008. View Article : Google Scholar : PubMed/NCBI
18	Zheng C, Zhou Q, Wu F, et al: Semaphorin3F down-regulates the expression of integrin alpha(v)beta3 and sensitizes multicellular tumor spheroids to chemotherapy via the neuropilin-2 receptor in vitro. Chemotherapy. 55:344–352. 2009. View Article : Google Scholar : PubMed/NCBI
19	Staton CA, Koay I, Wu JM, Hoh L, Reed MW and Brown NJ: Neuropilin-1 and neuropilin-2 expression in the adenoma-carcinoma sequence of colorectal cancer. Histopathology. 62:908–915. 2013. View Article : Google Scholar : PubMed/NCBI
20	Jia H, Cheng L, Tickner M, Bagherzadeh A, Selwood D and Zachary I: Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer. 102:541–552. 2010. View Article : Google Scholar : PubMed/NCBI
21	Chaudhary B, Khaled YS, Ammori BJ and Elkord E: Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother. 63:81–99. 2014. View Article : Google Scholar
22	Bruder D, Probst-Kepper M, Westendorf AM, et al: Neuropilin-1: A surface marker of regulatory T cells. Eur J Immunol. 34:623–630. 2004. View Article : Google Scholar : PubMed/NCBI
23	Renand A, Milpied P, Rossignol J, et al: Neuropilin-1 expression characterizes T follicular helper (Tfh) cells activated during B cell differentiation in human secondary lymphoid organs. PLoS One. 8:e855892013. View Article : Google Scholar
24	Chaudhary B, Khaled YS, Ammori BJ and Elkord E: Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother. 63:81–99. 2014. View Article : Google Scholar
25	Kamiya T, Kawakami T, Abe Y, et al: The preserved expression of neuropilin (NRP) 1 contributes to a better prognosis in colon cancer. Oncol Rep. 15:369–373. 2006.PubMed/NCBI
26	Wu YY, Chen YL, Jao YC, et al: miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar
27	Wan LY, Deng J, Xiang XJ, Zhang L, et al: miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 457:125–32. 2015. View Article : Google Scholar
28	Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC and Hong TM: miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar